{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=7", "query": { "intervention": "Arm 1- Dose Escalation", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:19:11.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03571568", "title": "A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Indolent B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BI-1206", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Acalabrutinib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioInvent International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2018-05-16", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Louisville, Kentucky", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03571568" }, { "nct_id": "NCT01111825", "title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2010-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 4, "location_summary": "Goodyear, Arizona • Los Angeles, California • New York, New York", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111825" }, { "nct_id": "NCT04256317", "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome/Neoplasm", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "ASTX030 (cedazuridine + azacitidine)", "type": "DRUG" }, { "name": "Cedazuridine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2020-05-21", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 24, "location_summary": "Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04256317" }, { "nct_id": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Rilvegostomig", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 452, "start_date": "2020-06-03", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379596" }, { "nct_id": "NCT04131413", "title": "HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papillomavirus Type 16", "Cervical Intraepithelial Neoplasia Grade II", "Cervical Intraepithelial Neoplasia, Grade III" ], "interventions": [ { "name": "pNGVL4aCRTE6E7L2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2020-09-14", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Baltimore, Maryland", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04131413" }, { "nct_id": "NCT00699582", "title": "To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Refractory Partial Seizures" ], "interventions": [ { "name": "E2007 (perampanel)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 389, "start_date": "2008-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 32, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00699582" }, { "nct_id": "NCT07311746", "title": "Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "T-cell Prolymphocytic Leukemia", "Refractory T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-04-28", "completion_date": "2031-01-31", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07311746" }, { "nct_id": "NCT04588922", "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "SLS009", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 160, "start_date": "2021-05-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04588922" }, { "nct_id": "NCT04649229", "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "LCZ 696", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Para-aminohippurate", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Aprepitant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-05-27", "completion_date": "2025-05-22", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649229" }, { "nct_id": "NCT02990481", "title": "A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Carcinomas", "Colon Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2017-03-06", "completion_date": "2019-09-16", "has_results": false, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-11-15T10:19:11.627Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02990481" } ] }